New combo aims to reboot immunotherapy in resistant cancers
NCT ID NCT04219254
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor shrinkage. About 197 participants will receive the combination intravenously or under the skin every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI-1206 (a monoclonal antibody) combined with pembrolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors who have stopped responding to standard immunotherapy.
- What could go wrong
- This is an early-phase trial (phase 1/2a) with a small number of participants. The drug may not work or could cause serious side effects. It is not yet proven to be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centrul de Oncologie SF Nectarie SRL
TERMINATEDCraiova, Romania
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Spain
-
HealthPartners Institute - Regions Cancer Care Center,
COMPLETEDSaint Paul, Minnesota, 55101, United States
-
Hm Ciocc Málaga
NOT_YET_RECRUITINGMálaga, Spain
-
Hospital Puerta de Hierro
RECRUITINGMajadahonda, Spain
-
Hospital Universitari Dexeus
RECRUITINGBarcelona, Spain
-
Hospital Universitari Vall D´Hebron
RECRUITINGBarcelona, Spain
-
Hospital Virgen de la Macarena
RECRUITINGSeville, Spain
-
Institut Català d'Oncologia Hospital Duran i Reynals
RECRUITINGBarcelona, Spain
-
Institutul Oncologic "Prof. Dr. Ion Chiricuta"
RECRUITINGCluj-Napoca, Romania
-
Instytut Centrum Zdrowia Matki Polki
TERMINATEDLodz, Poland
-
Israel-Georgian Medical Research Clinic Helsicore
TERMINATEDTbilisi, Georgia
-
Jerarsi Clinic
RECRUITINGTbilisi, Georgia
-
Karolinska University Hospital, Solna
RECRUITINGStockholm, Sweden
-
LTD High Technology Hospital Med Center
RECRUITINGBatumi, Georgia
-
Lund University Hospital
RECRUITINGLund, Sweden
-
Maria Skłodowska-Curie National Institute of Oncology
TERMINATEDGliwice, Poland
-
Medical University of Silesia
RECRUITINGKatowice, Poland
-
Medizinische Hochschule Hannover
RECRUITINGHanover, Germany
-
NEXT Oncology
COMPLETEDSan Antonio, Texas, 78229, United States
-
Nationales Centrum für Tumorerkrankungen
RECRUITINGHeidelberg, Germany
-
Oklahoma University , Stephenson Cancer Center
COMPLETEDOklahoma City, Oklahoma, 73104, United States
-
Sahlgrenska University Hospital
COMPLETEDGothenburg, Sweden
-
Sarah Cannon Research Institute
COMPLETEDDenver, Colorado, 80218, United States
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90024, United States
-
Universität des Saarlandes
RECRUITINGHomburg, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?